Diabetes is now the world’s fourth leading cause of death by illness, and the global epidemic shows no signs of abating. In recent decades, a revolution in science has contributed to a greater understanding of diabetes and the development of new cutting-edge therapies. However, diabetes prevalence, and diabetes-related death and disability have continued to grow rapidly. In order to identify, test and publish practical solutions to improve outcomes for people with diabetes throughout the world, the International Diabetes Federation (IDF) and Eli Lilly and Company have forged a partnership to fund and support translational research in the field of diabetes through IDF’s new grant research programme, Bringing Research in Diabetes to Global Environments and Systems (BRIDGES). The Chair of the BRIDGES Executive Committee, Jean-Claude Mbanya, outlines the aims and functions of the programme.
BRIDGES, translational research